Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Erythrocin Lactobionate
Synonyms :
erythromycin lactobionate
Class :
Brand Name :
Erythrocin Lactobionate
Synonyms :
erythromycin lactobionate
Class :
Dosage Forms & StrengthsÂ
InjectionÂ
500 mgÂ
Administer 500 mg intravenous every 6 hour for 3 days and followed by 500 mg orally every 12 hours
Group D Streptococcus InfectionsÂ
Take 250 mg orally every 12 hour
Renal Impairment
In case of creatinine clearance less than 10 ml/min: take 50 to 75% of the standard dosage
Dosing Form & StrengthsÂ
InjectionÂ
500 mgÂ
Refer to adult dosingÂ
measles, mumps, rubella, and varicella vaccine, live (Rx)
may diminish the therapeutic effect
measles mumps and rubella vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
smallpox (vaccinia) vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
It may enhance the effect when combined with miconazole vaginal by affecting CYP3A4 metabolism
nafcillin will decrease the effect of action of erythromycin lactobionate by affecting enzyme CYP3A4 metabolism.
QTc interval is increased both by lenvatinib and erythromycin lactobionate
erythromycin lactobionate increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
synthetic conjugated estrogens, bÂ
the activity of synthetic conjugated estrogens B is increased by erythromycin lactobionate
may increase the serum concentration of Vitamin K Antagonists
may increase the serum concentration of Vitamin K Antagonists
may increase the serum concentration of Vitamin K Antagonists
may increase the serum concentration of Vitamin K Antagonists
may increase the serum concentration of Vitamin K Antagonists
may increase the levels of serum concentration of cardiac glycosides
may increase the levels of serum concentration of cardiac glycosides
may increase the levels of serum concentration of cardiac glycosides
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
piperacillin decreases the effectiveness of erythromycin lactobionate by antagonism.
when both drugs combine erythromycin lactobionate will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
the effect of erythromycin lactobionate is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may reduce the therapeutic effect of typhoid Vaccine
lansoprazole amoxicillin and clarithromycin
when amoxicillin combines with erythromycin lactobionate it decreases the effects of action of drug by antagonism effect
amoxicillin and clavulanate potassium
when amoxicillin combines with erythromycin lactobionate it decreases the effects of action of drug by antagonism effect
omeprazole amoxicillin and clarithromycin
when amoxicillin combines with erythromycin lactobionate, it decreases the effects of the action of the drug by antagonism effect
when amoxicillin combines with erythromycin lactobionate, it decreases the effects of the action of the drug by antagonism effect
they increase the concentration of rilpivirine
Actions and SpectrumÂ
Antibiotic medications like erythromycin lactobionate are used to treat bacterial infections. It works by attaching to the bacterial ribosome and preventing protein synthesis, which ultimately causes the death of the bacteria.Â
erythromycin lactobionate has a wide range of gram-positive bacteria it can kill, including Corynebacterium, Staphylococcus, and Streptococcus species. It also works against some Gram-negative microorganisms.Â
Frequency defined Â
<1%Â
HypotensionÂ
ConfusionÂ
Nervous system effects including seizuresÂ
Ventricular tachycardiaÂ
VertigoÂ
HallucinationsÂ
Cholestatic hepatitisÂ
Hearing lossÂ
1-10%Â
Abdominal pain (8%)Â
Diarrhea (7%)Â
Vomiting (3%)Â
Hypertrophic pyloric stenosisÂ
AnaphylaxisÂ
FeverÂ
UrticariaÂ
Skin eruptionsÂ
TinnitusÂ
Ventricular arrhythmiasÂ
Dyspepsia (2%)Â
Pruritus (1%)Â
Mild allergic reactionsÂ
Rash (3%)Â
QT prolongationÂ
Venous irritationÂ
Pseudomembranous colitisÂ
Headache (8%)Â
Nausea (8%)Â
Flatulence (2%)Â
Pain (2%)Â
Post marketing reportsÂ
Interstitial nephritisÂ
Black Box WarningÂ
erythromycin lactobionate has a black box warning because it has the potential to cause cardiac arrhythmias, especially when administered at large doses or in those with pre-existing cardiac problems.
When erythromycin lactobionate is used with specific medicines, such as some antiarrhythmic medications or some antipsychotic medications, this risk is raised.Â
erythromycin lactobionate carries a black box warning indicating the possibility of hepatotoxicity, or liver damage. Patients who take erythromycin lactobionate for an extended period or those who already have liver disease are at higher risk.Â
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy warnings:    Â
Pregnancy category: BÂ Â
Lactation: Excretion into human milk is known Â
Pregnancy Categories:        Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There were lack of studies on pregnant women and no evidence of risk to the foetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
PharmacologyÂ
A macrolide antibiotic called erythromycin lactobionate works by preventing bacterial protein synthesis. It specifically attaches to the bacterial ribosome’s 50S subunit to stop the peptide chain from lengthening during translation.Â
PharmacodynamicsÂ
Streptococcus, Staphylococcus, and Corynebacterium species are only a few of the many Gram-positive bacteria that erythromycin lactobionate is successful against. Additionally, it is effective against some gram-negative bacteria like Moraxella catarrhalis and Haemophilus influenzae.Â
A few processes, including changes to the target site, active drug efflux, or enzymatic drug modification, might lead to resistance to erythromycin lactobionate.Â
PharmacokineticsÂ
Absorption  Â
Given intravenously, erythromycin lactobionate is completely absorbed and quickly reaches high concentrations in the blood and tissues.Â
DistributionÂ
The body has erythromycin lactobionate in large amounts, including in the heart, liver, kidneys, lungs and other organs. It can pass through the placenta and end up in breast milk.Â
MetabolismÂ
The primary cytochrome P450 system enzyme, CYP3A4, in the liver is responsible for erythromycin lactobionate metabolism and its main metabolite of erythromycin lactobionate.Â
Elimination and excretionÂ
erythromycin lactobionate is eliminated in the bile and urine, with 2 to 5% of the medication leaving the body unchanged. erythromycin lactobionate has an elimination half-life of about 1.5 hours, however patients with compromised liver or kidney function may experience a longer half-life.Â
Administration: Â
The medication erythromycin lactobionate is given intravenously. Â
To reduce the risk of infusion-related responses, erythromycin lactobionate should be infused gradually over a minimum of 20 to 30 minutes. In the same syringe or infusion bag, the medication should not be mixed with any other medications.Â
Patient information leafletÂ
Generic Name: erythromycin lactobionateÂ
Why do we use erythromycin lactobionate?Â
erythromycin lactobionate is used to treat infections brought by susceptible bacteria. Â
Streptococcus pneumoniae and Haemophilus influenzae-related respiratory tract infections are treated with erythromycin lactobionate.Â
Skin and soft tissue infections are managed with the help of erythromycin lactobionate. Â
Gastrointestinal tract infections are treated with erythromycin lactobionate.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
